Petruolo OA, et al. – This study was undertaken to investigate whether pathologic features can distinguish subsets likely to benefit from neoadjuvant chemotherapy (NAC). The results showed that estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2-) patients most likely to benefit from neoadjuvant chemotherapy (NAC) are those with progesterone receptor and high grade or poor tumors. It was indicated that patients with invasive lobular carcinoma (ILC) are unlikely to downstage in the breast or axilla compared with invasive ductal carcinoma. The use of these criteria can assist in characterizing the initial treatment approach.